|Articles|June 1, 2010

Applied Clinical Trials

  • Applied Clinical Trials-06-01-2010
  • Volume 0
  • Issue 0

Applied Clinical Trials Digital Edition - June 2010

GLOBAL TRIALS : New Survey Baselines Global Sites Keys to Success in China Budgeting for Global Trials European Ethics Committees CRO/SPONSOR : Think About the Drug Label First LABS : 3-Prong Model for CV Safety Immune Response Screens a Necessity eCLINICAL : ePRO?s Tipping Point Also in this issue : FDA?s New Risk Approach to Site Inspections, EMA Speaks to Stem Cell Research, Mother Lode of Latent Research Data

Articles in this issue

over 16 years ago

Biosimilars Make Headway

over 16 years ago

Business and News Update June 2010

over 16 years ago

Electronic Integration Costs

over 16 years ago

Strategic Immunogenicity Testing

over 16 years ago

ePRO vs. Paper

over 16 years ago

Today's Global Site Landscape

over 16 years ago

Changing Medicines, Changing Rules

over 16 years ago

Ethics Diversity Persists

over 16 years ago

Mastering Currency Fluctuation

over 16 years ago

Just Breathe: COPD, Asthma Future

Related to this article

The Next Evolution of Patient-Centered Trials Starts with Design
Decentralized trial success depends less on how far activities move away from sites than on matching each activity’s delivery model to participant burden, site readiness, and data integrity, using patient intelligence to decide where flexibility helps and where site-based care remains essential.
© putilov_denis - © putilov_denis - stock.adobe.com
Sponsors rigorously vet CROs for oncology expertise but rarely apply the same scrutiny to the IRB reviewing their trials, even though increasingly complex protocols require reviewers with substantive therapeutic knowledge, not just a rostered oncologist.